Chronic Lymphocytic Leukemia (CLL): How do we Manage Patients During COVID-19?

In this episode we discuss the management of CLL patients during the COVID-19 pandemic. 

Included is a discussion of:

• The initial treatment of patients with CLL during COVID-19
• The use of BTK inhibitors vs FCR
• The use of intravenous or subcutaneous immunoglobulin
• Existing guidelines for the treatment of CLL during COVID-19
• The virtual management of CLL patients

Our guest:

Dr. Pavic is a Medical Oncologist and Chief of the Hemato-Oncology department at the Centre intégré universitaire de santé et de services sociaux de l’Estrie – Centre Hospitalier Universitaire de Sherbrooke and an assistant professor in the Faculty of Medicine and Health Sciences at the Université de Sherbrooke.

Guidelines

• ASH recommendations: https://www.hematology.org/covid-19/covid-19-and-cll
• Canadian recommendations:  Management of chronic lymphocytic leukemia in Canada during the coronavirus pandemic: L.H. Sehn,  P. Kuruvilla, A. Christofides, J. Stakiw https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339858/pdf/conc-27-e332.pdf

**If you enjoy our podcast, please take the time to rate our podcast and subscribe**

For more great podcasts and other features, visit our website at: www.impactmedicom.com.